Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01626456 · ClinicalTrials.gov registry record · Phase 3
A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 3
- Development phase
- 478
- Enrollment target
NCT01626456 is a Phase 3 study that has completed, run by Alkermes. The registered enrollment target is 478 participants.
The verdict
NCT01626456, a Phase 3 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 478 participants
- Enrollment target
Study Summary
This study will evaluate the safety and durability of effect of ALKS 9072 (also known as ALKS 9070) during long-term treatment of subjects with stable schizophrenia.
Interventions
- DRUG ALKS 9072, Low
- DRUG ALKS 9072, High
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 478 participants |
| Start Date | 2012-06 |
| Est. Completion | 2015-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01626456
The ClinicalTrials.gov registry entry for NCT01626456 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 478 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ALKS 9072, Low is the first listed.
NCT01626456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01626456 about?
NCT01626456 is a clinical study titled "A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)". This study will evaluate the safety and durability of effect of ALKS 9072 (also known as ALKS 9070) during long-term treatment of subjects with stable schizophrenia.
What is the current status of trial NCT01626456?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 478 participants. The study started on 2012-06. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01626456?
The interventions under investigation include: ALKS 9072, Low (DRUG), ALKS 9072, High (DRUG).
Who is sponsoring clinical trial NCT01626456?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.